
Preliminary Population Pharmacokinetics Supports Phase 2 Dose Selection for Masked Anti–PD-L1 Antibody CX-072

¹CytomX Therapeutics, Inc., South San Francisco, California; ²Certara Strategic Consulting, Menlo Park, California; ³Applied BioMath, Lincoln, Massachusetts

BACKGROUND

- PROBODY therapeutic candidates (Pb-Tx) are antibody prodrugs with cleavable peptide masks designed to reduce off-tumor, on-target toxicities.¹ The mask is designed to inhibit Pb-Tx binding in the periphery yet can be removed by tumor-associated proteases, restricting target engagement to the tumor (**Figure 1**)
- Preliminary clinical pharmacokinetic (PK) analyses are reported here that support the selection of the Phase 2 dose for investigational Pb-Tx CX-072, an anti-programmed death-ligand 1 (PD-L1) Pb-Tx, from the ongoing Phase 1/2 PROCLAIM-CX-072 study (NCT03013491)^{2,3}




Pb-Tx, Probody therapeutic.

METHODS

- A quantitative systems pharmacology (QSP) model was used to project the CX-072 plasma trough level (C_{min}) corresponding to 95% intratumoral receptor occupancy (RO) (Figure 2)⁴
- Human PK and anti-drug antibody (ADA) data were obtained at selected times postdose following IV administration of 0.03 to 30 mg/kg CX-072 in the PROCLAIM-CX-072 study (**Tables 1 and 2**) Population PK (POPPK) modeling was performed with NONMEM v7.3.0 software
 - Exploratory analysis and simulations were done with R v3.3.1 or later
- Covariates were selected for POPPK using forward addition (P<0.05) followed by backward deletion (*P*<0.01)

Figure 2. The QSP model.




The CX-072 trough concentration corresponding to a targeted 95% intratumoral receptor occupancy was estimated using the QSP model, which accounts for events at the Pb-Tx, target, and compartmental levels. (A) Reversible events (bidirectional arrows) and irreversible cleavage reactions (unidirectional arrows) are captured. (B) These 6 forms of the Pb-Tx distribute to the plasma, peripheral, and tumor compartments. The Pb-Tx may engage in monovalent (step 1) or bivalent (step 2) binding to target. The Pb-Tx may be eliminated by nonspecific (step 3) and specific (target-mediated [step 5]) routes. Provisions for receptor trafficking and concentrations are included in the QSP model (step 4).

Pb-Tx, Probody therapeutic; QSP, quantitative systems pharmacology.

(Table 1, Figure 3)

Figure 3. Preliminary dose 1 median concentration of intact (solid lines) and total (dashed lines) CX-072 (nM) versus time (day) following administration of up to 30 mg/kg CX-072 Q2W in human patients and following intensive collection in the dose-escalation/biomarker and dose-effect cohorts.



The concentration profiles for intact CX-072 and total CX-072 appear similar at a given dose, suggesting that CX-072 circulates predominantly in the protected form. The similar elimination phase kinetics across the 0.1–30 mg/kg dose levels suggest limited importance of target-mediated drug disposition. a Dashed horizontal line represents the limit of quantitation (LOQ) for CX-072 assay. In representations below LOQ, data are assigned a value of LOQ/2

Monotherapy in PROCLAIM-CX-072^a

Dose, Route, and Regimen

0.03, 0.1, 0.3, 1, 3, 10, and 30 mg/kg IV infu Q2W beyond 2 years as long as patients continued to experience clinical benefit

EOI, end of infusion; EOT, end of treatment; IV, intravenous; PD ^a See Thistlethwaite F, et al. ASCO 2020 oral presentation. Abstr Prescribed PK collection under Amendment 5 of PROCLAIM-C ° EOT is approximately 30 days following last dose of study drug

Table 2. Analytes Assayed in the PROCLA

Analyte	
Intact CX-072	
Total CX-072	

American Society of Clinical Oncology Virtual Meeting, May 29–31, 2020

Mark Stroh,¹ Michelle Green,² B.L. Millard,³ Will Garner,¹ Hong Lu,¹ Jennifer Richardson,¹ Lawrence Lu,¹ Alison Hannah¹

RESULTS

 The preliminary POPPK analyses were informed using available PK data as of August 2019 from patients receiving CX-072 Q2W as monotherapy in the dose-escalation and expansion cohorts of PROCLAIM-CX-072

 Table 1. Overview of Data Used to Assess the Preliminary Clinical PK/PD of CX-072 Administered as

	Sampling Schedule ^b
usion	Dose-escalation/biomarker and dose-effect cohorts: Predose: cycle 1, day 1 (C1D1), C1D15, C1D29, C1D43, C2D1, C2D29, C3D1, C4D29, and every 4 cycles thereafter EOI + 30 min on C2D1 and C2D29 C1D1: EOI + 30 min, EOI + 24 h, EOI + 48 h, EOI + 168 h
	<u>Cohort expansion:</u> Predose: C1D1, C1D29, C2D1, C2D29, C4D29, and every 4 cycles thereafter EOI + 30 min on C1D1 and C2D29
	<u>All parts:</u> EOT,º follow-up visit
stract 3005. CX-072.	odynamics; PK, pharmacokinetics; Q2W, every 2 weeks.
AIM-C>	C-072 Study
	Description

Prodrug form of CX-072 Intact and activated forms of CX-072

- The preliminary POPPK model estimates for CX-072 time-invariant CL and volume of distribution at steady state were 0.306 L/day and 4.84 L, respectively (**Table 3**)
- The threshold for apparent ADA effect on CL in the ADA effect population (ADA_{decolin}) was fixed to 400 mg (5 mg/kg equivalent) based on log-likelihood profiling
- The interindividual variability was estimated to be 35.9% on CL. For patients receiving 10 mg/kg CX-072, the geometric mean (% coefficient of variation [CV]) intact CX-072 terminal half-life was 11.7 (33%) days; the fraction circulating as intact CX-072 was estimated at 87.2 (9.5%)


Table 3. Parameter Estimates for the Intact CX-072 Human POPPK Model

Parameter	Estimate	RSE (%)	
CL, L/day	0.306	4.06	
V1, L	3.35	2.99	
V2, L	1.49	12.7	
Q, L/day	0.487	24.6	
EMAX _{clada} , L/day	1.07	8.25	
Probability of ADA effect, %	64.6	15.6	
Log (CL _{ADA} TM50), days	2.80	2.05	
CL _{ADA} Hill coefficient	7.41	22.3	
ADA _{doselim} , mg	400		
Albumin on CL	-1.39	15.0	
Body weight on CL	0.553	24.1	
Body weight on V1	0.602	13.2	
σ^2 Proportional residual error, cycle 1	0.218	12.7	
σ^2 Proportional residual error, > cycle 1	0.292	14.3	
ω ² CL	0.129	9.99	
$\omega^2 V1$	0.0562	20.9	
$\omega^2 V2$	0.424	17.4	
Notos: ADA was fixed to values corresponding to the m	vinimum objective function value from	log likelihood profiling. The fraction of	ircul

Notes: ADA_{decesion} was fixed to values corresponding to the minimum objective function value from log-likelihood profiling. The fraction circulating as intact CX-072 was estimated based on the ratio of CL estimates for total to intact CX-072 for patients receiving 10 mg/kg CX-072. ω2, variance of omega; σ2, variance of sigma; ADA, antidrug antibody; ADA_{doselin}, threshold for apparent ADA effect on CL in the ADA effect population; CL, clearance; na, apparent ADA effect on CL; EMAX_{CLADA}, maximum increase in CL in the ADA effect population; IIV, interindividual variability; Q, intercompartmental clearance; RSE, relative standard error; TM50, time to half-maximal increase (in CL in the ADA effect population); V1, central volume, V2, peripheral volume.

- As has been reported for the PD-L1 inhibitor atezolizumab,⁵ preliminary multiple-dose data suggested a dose- and time-dependent effect of ADA on intact CX-072 exposures for some patients
- A mixture model was included in the POPPK evaluation to discriminate between patients who showed an apparent ADA effect on clearance (CL) and those who did not (Figure 4)

Figure 4. Preliminary human POPPK model diagram and diagnostics.




(A) Model diagram for CX-072 intact POPPK model that was parameterized with (B) time-invariant clearance for no ADA effect (CL) and time-dependent clearance for ADA effect ($CL+CL_{ADA}$) populations, respectively ADA, anti-drug antibody; POPPK, population pharmacokinetics

esidual or IIV (% CV)

21.8
29.2
35.9
23.7
65.1

CONCLUSIONS

- Preliminary PK analysis supports selection of 800 mg CX-072 Q2W as the recommended monotherapy dose and 800 mg Q3W × 4 when combined with ipilimumab (supported by available preliminary clinical [Thistlethwaite F, et al. ASCO 2020 oral presentation. Abstract 3005] and translational [Lyman SK, et al. ASCO 2020 poster. Abstract 3108] data obtained in PROCLAIM-CX-072)
- The QSP model that incorporated all cleaved and uncleaved species predicted that an intact CX-072 C_{min} of 13–99 nM would be required for the targeted 95% intratumoral RO assumed to be required for efficacy for the PD-L1 inhibitor atezolizumab.⁶ POPPK simulations suggested that >95% of patients receiving CX-072 10 mg/ kg Q2W would meet or exceed this targeted C_{min} regardless of ADA (**Figure 5**)
- Additional observed data indicated that the majority of patients receiving 10 mg/kg CX-072 Q3W × 4 with 3 mg/kg ipilimumab (IPI) Q3W × 4 in the CX-072-IPI combination part of PROCLAIM-CX-072-001 maintained the targeted C_{min}. Simulations suggested no clinically meaningful difference in exposure following a fixed dose of CX-072 800 mg relative to the 10 mg/kg weight-based dose (Figure 5B and 5C)
- The median model-estimated intra-individual area under the curve (AUC) ratio for intact CX-072 was 1.08 following CX-072 800 mg relative to CX-072 10 mg/kg



Simulated intact CX-072 PK profiles (solid line and shaded regions represent median and 90% prediction interval, respectively) following (A) 3 mg/kg, (B) 10 mg/kg, and (C) 800 mg Q2W CX-072. Dashed lines represent the target trough concentration range (13-99 nM) from the QSP model. (D) Simulated fraction of patients exceeding trough targets following the indicated dose of CX-072 Q2W following a single dose (left panel) and at steady state (right panel); dashed vertical line corresponds to 800 mg. The dose- and time-dependent effect of ADA on intact CX-072 exposures is evident in moving from the CX-072 3-mg/kg Q2W dose level, where a decreasing fraction of patients is projected to surpass the targeted C_{min} concentration range with multiple dosing, to the 10 mg/kg dose level, where >95% of patients are projected to

meet or exceed the targeted C_{min} regardless of ADAs. PK, pharmacokinetics; POPPK, population pharmacokinetics; Q2W, every 2 weeks; QSP, quantitative systems pharmacology; SS, steady state.

FUTURE DIRECTIONS FOR RESEARCH

• This study provides the preliminary PK analysis supporting the dose selection for CX-072, a Pb-Tx directed against PD-L1, for further evaluation in Phase 2 studies

References

1. Kavanaugh WM. *Expert Opin Biol Ther.* 2020;20:163-71. 2. Autio KA, et al. *J Clin Oncol.* 2018;36(15 Suppl):3071. 3. Naing A, et al. J Clin Oncol. 2019;37(15 Suppl):2513. 4. Stroh M, et al. CPT Pharmacometrics Syst Pharmacol. 2019;8:676-84. 5. Stroh M, et al. Clin Pharmacol Ther. 2017;102:305-12. 6. Deng R, et al. MAbs. 2016;8:593-603.

Acknowledgments

This study was sponsored by CytomX Therapeutics, Inc. Editorial assistance was provided by Echelon Brand Communications, an OPEN Health company, Parsippany, NJ, and was funded by CytomX Therapeutics, Inc. Email address for questions or comments: mstroh@cytomx.com